← All trials
NCT05027295
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2025
- First posted
- Aug 30, 2021
- Last posted
- Sep 21, 2021
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cornea and Laser Eye InstituteLead sponsor
- Hersh Vision GroupStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.